Press Releases

02/02/2024

Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research

Tempus, a leader in artificial intelligence and precision medicine, today announced the integration of its signature Tempus One technology into its Lens data analytics platform. The AI-enabled Tempus One technology will leverage advancements in generative AI to provide researchers the tools they need to seamlessly analyze Tempus’ de-identified...

01/24/2024

Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests

Tempus, a leader in artificial intelligence and precision medicine, today announced that the company has signed agreements for in-network provider status with Humana Inc. Under the agreement, Humana’s over 13 million members will have improved access to Tempus’ portfolio of molecular profiling tests in accordance with their medical policies, exp...

01/18/2024

Product Launch

Tempus Introduces xM MRD to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Data on xM presented at the 2024 ASCO® Gastrointestinal Cancers Symposium Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM MRD (formerly xM), to its comprehensive testing solutions. The tumor-naïve plasma based test is available for research use only to detect circulating tumor DNA (ctDNA) in th...

01/05/2024

Tempus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Tempus, a leader in artificial intelligence and precision medicine, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 8-11, 2024. Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with the investment community at the conference on M...

01/02/2024

Tempus Announces Participation in National Cancer Institute’s ComboMATCH Trials

Tempus, a leader in artificial intelligence and precision medicine, today announced its participation in the National Cancer Institute’s (NCI) ComboMATCH group of precision medicine trials. The ComboMATCH trials aim to pair patients with a therapy that has the potential to manage their tumor and help assist physicians in devisi...

11/28/2023

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Exclusive arrangement will expand market access to Personalis’ ultra-sensitive MRD test Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL) and Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis’ whole genome-based liqui...

11/20/2023

Tempus Welcomes City of Hope Comprehensive Cancer Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers represents over 30 medical centers that are leveraging the program to advance...

11/15/2023

Tempus Announces Medicare Coverage for Tempus xT Across Solid Tumor and Hematologic Malignancies

Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’ CAP/CLIA laborator...

11/09/2023

Tempus Announces New Strategic Collaboration with Recursion to Advance Therapeutic Development

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working together to advance biomarker-driven therapeutic development with a data-first approach. Through this coll...

11/08/2023

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease mode...

NEWS

Media Coverage

Additional Partnerships